Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:MYO
Previous Symbol
CUSIPN/A
Phone+1-617-9969058
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees22
Outstanding Shares12,440,000
Market Cap$0.00
OptionableNot Optionable
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) announced its quarterly earnings data on Monday, November, 5th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.01. The company had revenue of $0.61 million for the quarter, compared to analysts' expectations of $0.82 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What price target have analysts set for MYO?
2 brokers have issued 1 year price targets for Myomo's shares. Their predictions range from $7.00 to $12.00. On average, they anticipate Myomo's stock price to reach $9.50 in the next year. This suggests a possible upside of 455.0% from the stock's current price. View Analyst Price Targets for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
Media coverage about MYO stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myomo earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Are investors shorting Myomo?
Myomo saw a drop in short interest in the month of November. As of November 30th, there was short interest totalling 813,452 shares, a drop of 1.9% from the November 15th total of 829,262 shares. Based on an average daily trading volume, of 77,403 shares, the short-interest ratio is currently 10.5 days. Currently, 7.9% of the shares of the company are short sold. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Activecare (ACAR), Advanced Oncotherapy (AVO), Airware Labs (AIRW), Anteo Diagnostics (ADO), Aurora Spine (ASG), Avacta Group (AVCT), Azure Healthcare (AZV), Biosig Technologies (BSGM), Cannabix Technologies (BLOZF), Cochlear (COH), ConvaTec Group (CTEC), Creo Medical Group (CREO), Draegerwerk AG & Co KGaA (DRW3), Electromed (ELMD) and Ellex Medical Lasers (ELXMF).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $1.7117.
What is Myomo's official website?
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
